Galectin Therapeutics, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Co.'s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. Co.'s lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. We show 53 historical shares outstanding datapoints in our coverage of GALT's shares outstanding history.
Understanding the changing numbers of GALT shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like GALT versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching GALT by allowing them to research GALT shares outstanding history
as well as any other stock in our coverage universe. |
Free GALT Email Alerts:
Video: Shares Outstanding Importance
